nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.12.2013

Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells

verfasst von: Sui Huang

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3-4/2013

Einloggen, um Zugang zu erhalten

Abstract

Genetic instability is invoked in explaining the cell phenotype changes that take place during cancer progression. However, the coexistence of a vast diversity of distinct clones, most prominently visible in the form of non-clonal chromosomal aberrations, suggests that Darwinian selection of mutant cells is not operating at maximal efficacy. Conversely, non-genetic instability of cancer cells must also be considered. Such mutation-independent instability of cell states is most prosaically manifest in the phenotypic heterogeneity within clonal cell populations or in the reversible switching between immature “cancer stem cell-like” and more differentiated states. How are genetic and non-genetic instability related to each other? Here, we review basic theoretical foundations and offer a dynamical systems perspective in which cancer is the inevitable pathological manifestation of modes of malfunction that are immanent to the complex gene regulatory network of the genome. We explain in an accessible, qualitative, and permissively simplified manner the mathematical basis for the “epigenetic landscape” and how the latter relates to the better known “fitness landscape.” We show that these two classical metaphors have a formal basis. By combining these two landscape concepts, we unite development and somatic evolution as the drivers of the relentless increase in malignancy. Herein, the cancer cells are pushed toward cancer attractors in the evolutionarily unused regions of the epigenetic landscape that encode more and more “dedifferentiated” states as a consequence of both genetic (mutagenic) and non-genetic (regulatory) perturbations—including therapy. This would explain why for the cancer cell, the principle of “What does not kill me makes me stronger” is as much a driving force in tumor progression and development of drug resistance as the simple principle of “survival of the fittest.”

Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998). Genetic instabilities in human cancers. Nature, 396(6712), 643–649.PubMed

Cahill, D. P., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (1999). Genetic instability and Darwinian selection in tumours. Trends in Cell Biology, 9(12), M57–M60.PubMed

Attolini, C. S., & Michor, F. (2009). Evolutionary theory of cancer. Annals of the New York Academy of Sciences, 1168, 23–51. doi:10.1111/j.1749-6632.2009.04880.x (Review).PubMed

Nowak, M. A., Michor, F., & Iwasa, Y. (2006). Genetic instability and clonal expansion. Journal of Theoretical Biology, 241(1), 26–32. doi:10.1016/j.jtbi.2005.11.012.PubMed

Heng, H. H., Stevens, J. B., Bremer, S. W., Ye, K. J., Liu, G., & Ye, C. J. (2010). The evolutionary mechanism of cancer. Journal of Cellular Biochemistry, 109(6), 1072–1084. doi:10.1002/jcb.22497.PubMed

McCullough, K. D., Coleman, W. B., Ricketts, S. L., Wilson, J. W., Smith, G. J., & Grisham, J. W. (1998). Plasticity of the neoplastic phenotype in vivo is regulated by epigenetic factors. Proceedings of the National Academy of Sciences of the United States of America, 95(26), 15333–15338.PubMed

Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., et al. (2011). Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell, 146(4), 633–644. doi:10.1016/j.cell.2011.07.026 (Research support, non-U.S. government).PubMed

Chaffer, C. L., Brueckmann, I., Scheel, C., Kaestli, A. J., Wiggins, P. A., Rodrigues, L. O., et al. (2011). Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proceedings of the National Academy of Sciences of the United States of America, 108(19), 7950–7955. doi:10.1073/pnas.1102454108.PubMed

Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell, 141(4), 583–594. doi:10.1016/j.cell.2010.04.020.PubMed

10.

Dean, M., Fojo, T., & Bates, S. (2005). Tumour stem cells and drug resistance. Nature Reviews. Cancer, 5(4), 275–284.PubMed

11.

Hoek, K. S., & Goding, C. R. (2010). Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell & Melanoma Research, 23(6), 746–759. doi:10.1111/j.1755-148X.2010.00757.x (Comparative study review).

12.

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141(1), 69–80. doi:10.1016/j.cell.2010.02.027.PubMed

13.

Huang, S. (2012). Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution. Progress in Biophysics and Molecular Biology, 110(1), 69–86.PubMed

14.

Holmberg, J., & Perlmann, T. (2012). Maintaining differentiated cellular identity. Nature Reviews. Genetics, 13(6), 429–439. doi:10.1038/nrg3209 (Research support, non-U.S. government. Review).PubMed

15.

Sawyers, C. L., Denny, C. T., & Witte, O. N. (1991). Leukemia and the disruption of normal hematopoiesis. Cell, 64(2), 337–350 (Research support, non-U.S. government. Review).PubMed

16.

Virchow, R. L. K. (1978). Cellular pathology (1859th ed., pp. 204–207). London: John Churchill.

17.

Deutscher, G. (2010). Through the language glass: why the world looks different in other languages (1st ed.). New York: Macmillan.

18.

Huang, S. (2012). The molecular and mathematical basis of Waddington’s epigenetic landscape: a framework for post-Darwinian biology. BioEssays, 34(2), 149–155.PubMed

19.

Sieber, O., Heinimann, K., & Tomlinson, I. (2005). Genomic stability and tumorigenesis. Seminars in Cancer Biology, 15(1), 61–66. doi:10.1016/j.semcancer.2004.09.005.PubMed

20.

Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic instability—an evolving hallmark of cancer. Nature Reviews. Molecular Cell Biology, 11(3), 220–228. doi:10.1038/nrm2858.PubMed

21.

Beckman, R. A. (2010). Efficiency of carcinogenesis: is the mutator phenotype inevitable? Seminars in Cancer Biology, 20(5), 340–352. doi:10.1016/j.semcancer.2010.10.004 (Review).PubMed

22.

Bielas, J. H., & Loeb, L. A. (2005). Mutator phenotype in cancer: timing and perspectives. Environmental and Molecular Mutagenesis, 45(2–3), 206–213.PubMed

23.

Huang, S., & Ingber, D. E. (2000). Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks. Experimental Cell Research, 261(1), 91–103.PubMed

24.

Huang, S. (2009). Non-genetic heterogeneity of cells in development: more than just noise. Development, 136(23), 3853–3862. doi:10.1242/dev.035139.PubMed

25.

Altschuler, S. J., & Wu, L. F. (2010). Cellular heterogeneity: do differences make a difference? Cell, 141(4), 559–563. doi:10.1016/j.cell.2010.04.033.PubMed

26.

Stewart, J. M., Shaw, P. A., Gedye, C., Bernardini, M. Q., Neel, B. G., & Ailles, L. E. (2011). Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America, 108(16), 6468–6473. doi:10.1073/pnas.1005529108.PubMed

27.

Baum, B., Settleman, J., & Quinlan, M. P. (2008). Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol, 19(3), 294–308. doi:10.1016/j.semcdb.2008.02.001.PubMed

28.

Singh, A., & Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 29(34), 4741–4751. doi:10.1038/onc.2010.215.PubMed

29.

Bonifer, C. (2005). Epigenetic plasticity of hematopoietic cells. Cell Cycle, 4(2), 211–214.PubMed

30.

Frisen, J. (2002). Stem cell plasticity? Neuron, 35(3), 415–418.PubMed

31.

Joshi, C. V., & Enver, T. (2002). Plasticity revisited. Current Opinion in Cell Biology, 14(6), 749–755.PubMed

32.

Raff, M. (2003). Adult stem cell plasticity: fact or artifact? Annual Review of Cell and Developmental Biology, 19, 1–22.PubMed

33.

Gotzmann, J., Mikula, M., Eger, A., Schulte-Hermann, R., Foisner, R., Beug, H., et al. (2004). Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutation Research, 566(1), 9–20.PubMed

34.

Spencer, S. L., Gerety, R. A., Pienta, K. J., & Forrest, S. (2006). Modeling somatic evolution in tumorigenesis. PLoS Computational Biology, 2(8), e108.PubMed

35.

Vogelstein, B., & Kinzler, K. W. (1993). The multistep nature of cancer. Trends in Genetics, 9(4), 138–141.PubMed

36.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. doi:10.1016/j.cell.2011.02.013 (Research support, N.I.H. Extramural review).PubMed

37.

Huang, S. (2011). Systems biology of stem cells: three useful perspectives to help overcome the paradigm of linear pathways. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 366(1575), 2247–2259. doi:10.1098/rstb.2011.0008.PubMed

38.

Huang, S., & Kauffman, S. (2009). Complex gene regulatory networks—from structure to biological observables: cell fate determination. In R. A. Meyers (Ed.), Encyclopedia of complexity and systems science. Heidelberg: Springer, 1180–1213.

39.

Huang, S. (2009). Reprogramming cell fates: reconciling rarity with robustness. BioEssays, 31(5), 546–560. doi:10.1002/bies.200800189.PubMed

40.

Eldar, A., & Elowitz, M. B. (2010). Functional roles for noise in genetic circuits. Nature, 467(7312), 167–173. doi:10.1038/nature09326.PubMed

41.

Kaern, M., Elston, T. C., Blake, W. J., & Collins, J. J. (2005). Stochasticity in gene expression: from theories to phenotypes. Nature Reviews. Genetics, 6(6), 451–464.PubMed

42.

Raj, A., & van Oudenaarden, A. (2008). Nature, nurture, or chance: stochastic gene expression and its consequences. Cell, 135(2), 216–226. doi:10.1016/j.cell.2008.09.050.PubMed

43.

Huang, S. (2010). Cell lineage determination in state space: a systems view brings flexibility to dogmatic canonical rules. PLoS Biology, 8(5), e1000380. doi:10.1371/journal.pbio.1000380.PubMed

44.

Zhou, J. X., Aliyu, M. D., Aurell, E., & Huang, S. (2012). Quasi-potential landscape in complex multi-stable systems. Journal of the Royal Society, Interface, 9(77), 3539–3553. doi:10.1098/rsif.2012.0434.PubMed

45.

Ferrell, J. E., & Xiong, W. (2001). Bistability in cell signaling: how to make continuous processes discontinuous, and reversible processes irreversible. Chaos, 11(1), 227–236. doi:10.1063/1.1349894.PubMed

46.

Tyson, J. J., Chen, K. C., & Novak, B. (2003). Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. Current Opinion in Cell Biology, 15(2), 221–231.PubMed

47.

Huang, S. (2001). Genomics, complexity and drug discovery: insights from Boolean network models of cellular regulation. Pharmacogenomics, 2(3), 203–222.PubMed

48.

Waddington, C. H. (1957). The strategy of the genes. London: Allen and Unwin.

49.

Kauffman, S. (1969). Homeostasis and differentiation in random genetic control networks. Nature, 224(215), 177–178.PubMed

50.

Ptashne, M. (2007). On the use of the word ‘epigenetic’. Current Biology, 17(7), R233–R236.PubMed

51.

Bird, A. (2007). Perceptions of epigenetics. Nature, 447(7143), 396–398.PubMed

52.

Holliday, R. (2005). DNA methylation and epigenotypes. Biochemistry (Mosc), 70(5), 500–504.

53.

Kouzarides, T. (2007). Chromatin modifications and their function. Cell, 128(4), 693–705.PubMed

54.

Kubicek, S., & Jenuwein, T. (2004). A crack in histone lysine methylation. Cell, 119(7), 903–906.PubMed

55.

Trojer, P., & Reinberg, D. (2006). Histone lysine demethylases and their impact on epigenetics. Cell, 125(2), 213–217.PubMed

56.

Bonifer, C., Hoogenkamp, M., Krysinska, H., & Tagoh, H. (2008). How transcription factors program chromatin—lessons from studies of the regulation of myeloid-specific genes. Seminars in Immunology, 20(4), 257–263. doi:10.1016/j.smim.2008.05.001.PubMed

57.

Suter, D. M., Molina, N., Naef, F., & Schibler, U. (2011). Origins and consequences of transcriptional discontinuity. Current Opinion in Cell Biology, 23(6), 657–662. doi:10.1016/j.ceb.2011.09.004.PubMed

58.

Lynch, M. (2007). Colloquium papers: the frailty of adaptive hypotheses for the origins of organismal complexity. Proceedings of the National Academy of Sciences of the United States of America, 104(Suppl 1), 8597–8604.PubMed

59.

Nowak, M. A. (2006). Evolutionary dynamics: exploring the equations of life (1st ed.). Cambridge, MA: Belknap.

60.

Wright, S. (1945). The differential equation of the distribution of gene frequencies. Proceedings of the National Academy of Sciences of the United States of America, 31(12), 382–389.PubMed

61.

Kauffman, S. A. (1993). The origins of order. New York: Oxford University Press.

62.

Galhardo, R. S., Hastings, P. J., & Rosenberg, S. M. (2007). Mutation as a stress response and the regulation of evolvability. Critical Reviews in Biochemistry and Molecular Biology, 42(5), 399–435. doi:10.1080/10409230701648502 (Research support, N.I.H. Extramural review).PubMed

63.

Brutovsky, B., & Horvath, D. (2010). Optimization aspects of carcinogenesis. Medical Hypotheses, 74(5), 922–927. doi:10.1016/j.mehy.2009.10.019 (Research support, non-U.S. government).PubMed

64.

Bielas, J. H., Loeb, K. R., Rubin, B. P., True, L. D., & Loeb, L. A. (2006). Human cancers express a mutator phenotype. Proceedings of the National Academy of Sciences of the United States of America, 103(48), 18238–18242.PubMed

65.

Cairns, J. (1975). Mutation selection and the natural history of cancer. Nature, 255(5505), 197–200.PubMed

66.

Klein, C. A. (2009). Parallel progression of primary tumours and metastases. Nature Reviews. Cancer, 9(4), 302–312. doi:10.1038/nrc2627.PubMed

67.

Bernards, R., & Weinberg, R. A. (2002). A progression puzzle. Nature, 418(6900), 823.PubMed

68.

Brock, A., Chang, H., & Huang, S. (2009). Non-genetic heterogeneity—a mutation-independent driving force for the somatic evolution of tumours. Nature Reviews. Genetics, 10(5), 336–342. doi:10.1038/nrg2556.PubMed

69.

Gould, S. J. (1997). Darwinian fundamentalism. New York Review of Books (June 12), pp. 34–37.

70.

Gould, S. J., & Lewontin, R. C. (1979). The spandrels of San Marco and the Panglossian paradigm: a critique of the adaptationist programme. Proceedings of the Royal Society of London. Series B: Biological Sciences, 205(1161), 581–598.

71.

Lewontin, R. C. (2000). The triple helix: gene, organism, and environment (2001st ed.). Cambridge, MA: Harvard University Press.

72.

Rose, S., Kamin, L. J., & Lewontin, R. C. (1985). Not in our genes: biology, ideology, and human nature. New York: Pantheon.

73.

Pigliucci, M. (2009). An extended synthesis for evolutionary biology. Annals of the New York Academy of Sciences, 1168, 218–228. doi:10.1111/j.1749-6632.2009.04578.x.PubMed

74.

Noble, D. (2011). Neo-Darwinism, the modern synthesis and selfish genes: are they of use in physiology? The Journal of Physiology, 589(Pt 5), 1007–1015. doi:10.1113/jphysiol.2010.201384 (Research support, non-U.S. government. Review).PubMed

75.

Eldredge, N., & Gould, S. J. (1997). On punctuated equilibria. Science, 276(5311), 338–341 (Comment letter).PubMed

76.

Caporale, L. H. (2009). Putting together the pieces: evolutionary mechanisms at work within genomes: can we suggest molecular underpinnings of punctuated equilibria and the Cambrian explosion? BioEssays, 31(7), 700–702. doi:10.1002/bies.200900067.PubMed

77.

Gould, S. J. (1994). Tempo and mode in the macroevolutionary reconstruction of Darwinism. Proceedings of the National Academy of Sciences of the United States of America, 91(15), 6764–6771 (Review).PubMed

78.

Heng, H. H., Bremer, S. W., Stevens, J., Ye, K. J., Miller, F., Liu, G., et al. (2006). Cancer progression by non-clonal chromosome aberrations. Journal of Cellular Biochemistry, 98(6), 1424–1435. doi:10.1002/jcb.20964 (Comparative study. Research support, non-U.S. government. Review).PubMed

79.

Heng, H. H., Stevens, J. B., Bremer, S. W., Liu, G., Abdallah, B. Y., & Ye, C. J. (2011). Evolutionary mechanisms and diversity in cancer. Advances in Cancer Research, 112, 217–253. doi:10.1016/B978-0-12-387688-1.00008-9 (Research support, non-U.S. government, non-P.H.S. Review).PubMed

80.

Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., et al. (2011). Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell, 144(1), 27–40. doi:10.1016/j.cell.2010.11.055.PubMed

81.

Huang, S., Ernberg, I., & Kauffman, S. (2009). Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Seminars in Cell & Developmental Biology, 20(7), 869–876. doi:10.1016/j.semcdb.2009.07.003.

82.

Davies, P. C., & Lineweaver, C. H. (2011). Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors. Physical Biology, 8((1), 015001. doi:10.1088/1478-3975/8/1/015001 (Research support, N.I.H., Extramural).

83.

Ben-Jacob, E., Coffey, D. S., & Levine, H. (2012). Bacterial survival strategies suggest rethinking cancer cooperativity. Trends in Microbiology, 20(9), 403–410. doi:10.1016/j.tim.2012.06.001.PubMed

84.

Kauffman, S. (1971). Differentiation of malignant to benign cells. Journal of Theoretical Biology, 31(3), 429–451.PubMed

85.

Huang, S. (2011). On the intrinsic inevitability of cancer: from foetal to fatal attraction. Seminars in Cancer Biology, 21(3), 183–199. doi:10.1016/j.semcancer.2011.05.003.PubMed

86.

Aldana, M., Balleza, E., Kauffman, S., & Resendiz, O. (2007). Robustness and evolvability in genetic regulatory networks. Journal of Theoretical Biology, 245(3), 433–448.PubMed

87.

Torres-Sosa, C., Huang, S., & Aldana, M. (2012). Criticality is an emergent property of genetic networks that exhibit evolvability. PLoS Computational Biology, 8(9), e1002669. doi:10.1371/journal.pcbi.1002669 (Research support, non-U.S. government).PubMed

88.

Sonnenschein, C., & Soto, A. M. (1998). The society of cells: cancer and control of cell proliferation. Philadelphia, PA: Garland Science.

89.

Raff, M. C. (1992). Social controls on cell survival and cell death. Nature, 356(6368), 397–400.PubMed

90.

Paulovich, A. G., Toczyski, D. P., & Hartwell, L. H. (1997). When checkpoints fail. Cell, 88(3), 315–321.PubMed

91.

Hernando, E., Nahle, Z., Juan, G., Diaz-Rodriguez, E., Alaminos, M., Hemann, M., et al. (2004). Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature, 430(7001), 797–802.PubMed

92.

Mantel, C., Guo, Y., Lee, M. R., Kim, M. K., Han, M. K., Shibayama, H., et al. (2007). Checkpoint–apoptosis uncoupling in human and mouse embryonic stem cells: a source of karyotpic instability. Blood, 109(10), 4518–4527. doi:10.1182/blood-2006-10-054247 (Research support, N.I.H., non-U.S. government. Extramural).PubMed

93.

Erenpreisa, J., & Cragg, M. S. (2007). Cancer: a matter of life cycle? Cell Biology International, 31(12), 1507–1510. doi:10.1016/j.cellbi.2007.08.013 (Review).PubMed

94.

Balleza, E., Alvarez-Buylla, E. R., Chaos, A., Kauffman, A., Shmulevich, I., & Aldana, M. (2008). Critical dynamics in genetic regulatory networks: examples from four kingdoms. PLoS One, 3, e2456.PubMed

95.

Shmulevich, I., Kauffman, S. A., & Aldana, M. (2005). Eukaryotic cells are dynamically ordered or critical but not chaotic. Proceedings of the National Academy of Sciences of the United States of America, 102(38), 13439–13444.PubMed

96.

Mitsiadis, T. A., Caton, J., & Cobourne, M. (2006). Waking-up the sleeping beauty: recovery of the ancestral bird odontogenic program. Journal of Experimental Zoology. Part B, Molecular and Developmental Evolution, 306(3), 227–233. doi:10.1002/jez.b.21094 (Research support, non-U.S. government. Comparative study).PubMed

97.

Newman, S. A. (2011). Thermogenesis, muscle hyperplasia, and the origin of birds. BioEssays, 33(9), 653–656. doi:10.1002/bies.201100061 (Research support, U.S. government, non-P.H.S.).PubMed

98.

Kitada, K., Taima, A., Ogasawara, K., Metsugi, S., & Aikawa, S. (2011). Chromosome-specific segmentation revealed by structural analysis of individually isolated chromosomes. Genes, Chromosomes & Cancer, 50(4), 217–227. doi:10.1002/gcc.20847.

99.

Li, R., Yerganian, G., Duesberg, P., Kraemer, A., Willer, A., Rausch, C., et al. (1997). Aneuploidy correlated 100 % with chemical transformation of Chinese hamster cells. Proceedings of the National Academy of Sciences of the United States of America, 94(26), 14506–14511.PubMed

100.

Clark, W. H. (1991). Tumour progression and the nature of cancer. British Journal of Cancer, 64(4), 631–644.PubMed

101.

Mitchison, T. J. (2012). The proliferation rate paradox in antimitotic chemotherapy. Molecular Biology of the Cell, 23(1), 1–6. doi:10.1091/mbc.E10-04-0335 (Research support, N.I.H. Extramural).PubMed

102.

Persons, D. L., Yazlovitskaya, E. M., Cui, W., & Pelling, J. C. (1999). Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clinical Cancer Research, 5(5), 1007–1014 (Research support, U.S. government, P.H.S. Comparative study).PubMed

103.

Sims, A. H., Zweemer, A. J., Nagumo, Y., Faratian, D., Muir, M., Dodds, M., et al. (2012). Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. British Journal of Cancer, 106(11), 1779–1789. doi:10.1038/bjc.2012.176 (Research support, non-U.S. government).PubMed

104.

Levsky, J. M., & Singer, R. H. (2003). Gene expression and the myth of the average cell. Trends in Cell Biology, 13(1), 4–6.PubMed

105.

Chang, H. H., Hemberg, M., Barahona, M., Ingber, D. E., & Huang, S. (2008). Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature, 453(7194), 544–547.PubMed

106.

Cohen, A. A., Geva-Zatorsky, N., Eden, E., Frenkel-Morgenstern, M., Issaeva, I., Sigal, A., et al. (2008). Dynamic proteomics of individual cancer cells in response to a drug. Science, 322, 1511–1516.

107.

Spencer, S. L., Gaudet, S., Albeck, J. G., Burke, J. M., & Sorger, P. K. (2009). Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature, 459(7245), 428–432. doi:10.1038/nature08012.PubMed

108.

Darwin, C. (1869). On the origin of species by means of natural selection, or the preservation of favoured races in the struggle for life (5th ed., pp. 91–92). London: John Murray.

109.

Nietzsche, F. (1998). Twilight of the idols (D. Large, trans.). Oxford: Oxford University Press.

110.

Dirks, P. (2010). Cancer stem cells: invitation to a second round. Nature, 466(7302), 40–41. doi:10.1038/466040a.PubMed

111.

Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009). Cancer stem cells: mirage or reality? Nature Medicine, 15(9), 1010–1012. doi:10.1038/nm0909-1010.PubMed

112.

Hill, R. P., & Perris, R. (2007). “Destemming” cancer stem cells. Journal of the National Cancer Institute, 99(19), 1435–1440.PubMed

113.

Jordan, C. T. (2009). Cancer stem cells: controversial or just misunderstood? Cell Stem Cell, 4(3), 203–205. doi:10.1016/j.stem.2009.02.003.PubMed

114.

Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L., & Strasser, A. (2007). Tumor growth need not be driven by rare cancer stem cells. Science, 317(5836), 337. doi:10.1126/science.1142596.PubMed

115.

Lobo, N. A., Shimono, Y., Qian, D., & Clarke, M. F. (2007). The biology of cancer stem cells. Annual Review of Cell and Developmental Biology, 23, 675–699. doi:10.1146/annurev.cellbio.22.010305.104154.PubMed

116.

Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414(6859), 105–111.PubMed

117.

Blick, T., Widodo, E., Hugo, H., Waltham, M., Lenburg, M. E., Neve, R. M., et al. (2008). Epithelial mesenchymal transition traits in human breast cancer cell lines. Clinical & Experimental Metastasis, 25(6), 629–642.

118.

Deka, J., Wiedemann, N., Anderle, P., Murphy-Seiler, F., Bultinck, J., Eyckerman, S., et al. (2010). Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Research, 70(16), 6619–6628. doi:10.1158/0008-5472.CAN-10-0148.PubMed

119.

Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell, 133(4), 704–715.PubMed

120.

Donnenberg, V. S., & Donnenberg, A. D. (2005). Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. The Journal of Clinical Pharmacology, 45(8), 872–877.

121.

Elliot, A., Adams, J., & Al-Hajj, M. (2010). The ABCs of cancer stem cell drug resistance. IDrugs, 13(9), 632–635.PubMed

122.

Lee, G. Y., Shim, J. S., Cho, B., Jung, J. Y., Lee, D. S., & Oh, I. H. (2011). Stochastic acquisition of a stem cell-like state and drug tolerance in leukemia cells stressed by radiation. International Journal of Hematology, 93(1), 27–35. doi:10.1007/s12185-010-0734-2 (Research support, non-U.S. government).PubMed

123.

Ghisolfi, L., Keates, A. C., Hu, X., Lee, D. K., & Li, C. J. (2012). Ionizing radiation induces stemness in cancer cells. PLoS One, 7(8), e43628. doi:10.1371/journal.pone.0043628 (Research support, non-U.S. government).PubMed

124.

Andarawewa, K. L., Erickson, A. C., Chou, W. S., Costes, S. V., Gascard, P., Mott, J. D., et al. (2007). Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer Research, 67(18), 8662–8670. doi:10.1158/0008-5472.CAN-07-1294 (Research support, U.S. government, non-P.H.S.).PubMed

125.

Arumugam, T., Ramachandran, V., Fournier, K. F., Wang, H., Marquis, L., Abbruzzese, J. L., et al. (2009). Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Research, 69(14), 5820–5828. doi:10.1158/0008-5472.CAN-08-2819.PubMed

126.

Li, Q. Q., Xu, J. D., Wang, W. J., Cao, X. X., Chen, Q., Tang, F., et al. (2009). Twist1-mediated adriamycin-induced epithelial–mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clinical Cancer Research, 15(8), 2657–2665. doi:10.1158/1078-0432.CCR-08-2372 (Research support, non-U.S. government).PubMed

127.

Li, Q. Q., Chen, Z. Q., Cao, X. X., Xu, J. D., Xu, J. W., Chen, Y. Y., et al. (2011). Involvement of NF-kappaB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial–mesenchymal transition of breast cancer cells. Cell Death and Differentiation, 18(1), 16–25. doi:10.1038/cdd.2010.103 (Research support, non-U.S. government).PubMed

128.

Wang, Z., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A. S., et al. (2009). Acquisition of epithelial–mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Research, 69(6), 2400–2407. doi:10.1158/0008-5472.CAN-08-4312 (Research support, N.I.H., non-U.S. government. Extramural).PubMed

129.

Chaudhary, P. M., & Roninson, I. B. (1993). Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. Journal of the National Cancer Institute, 85(8), 632–639.PubMed

130.

Abolhoda, A., Wilson, A. E., Ross, H., Danenberg, P. V., Burt, M., & Scotto, K. W. (1999). Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clinical Cancer Research, 5(11), 3352–3356.PubMed

131.

Stein, U., Jurchott, K., Walther, W., Bergmann, S., Schlag, P. M., & Royer, H. D. (2001). Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. The Journal of Biological Chemistry, 276(30), 28562–28569. doi:10.1074/jbc.M100311200 (Research support, non-U.S. government).PubMed

132.

Chin, K. V., Tanaka, S., Darlington, G., Pastan, I., & Gottesman, M. M. (1990). Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. The Journal of Biological Chemistry, 265(1), 221–226.PubMed

133.

Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature, 463(7278), 191–196. doi:10.1038/nature08658.PubMed

134.

Yates, L. R., & Campbell, P. J. (2012). Evolution of the cancer genome. Nature Reviews. Genetics, 13(11), 795–806. doi:10.1038/nrg3317.PubMed

135.

Kreso, A., O'Brien, C. A., van Galen, P., Gan, O. I., Notta, F., Brown, A. M., et al. (2013). Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science, 339(6119), 543–548. doi:10.1126/science.1227670.PubMed

136.

Nobili, S., Landini, I., Mazzei, T., & Mini, E. (2012). Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Medicinal Research Reviews, 32, 1220–1262. doi:10.1002/med.20239.PubMed

Titel: Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells
verfasst von: Sui Huang
Publikationsdatum: 01.12.2013
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3-4/2013
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-013-9435-7

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells

Abstract

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3-4/2013

Update on clinical and mechanistic aspects of paraneoplastic syndromes

Do mutator mutations fuel tumorigenesis?

The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression

Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review

The detection and implication of genome instability in cancer

Tumor type-specific and skin region-selective metastasis of human cancers: another example of the “seed and soil” hypothesis

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie